Beijing Derun Liuhe Pharmaceutical Technology

Beijing Derun Liuhe Pharmaceutical Technology is a China-based biopharmaceutical company focused on the research, development, and commercialization of innovative small molecule drugs and high-end generics. The company's primary therapeutic focus includes cardiovascular and cerebrovascular diseases, oncology, and metabolic disorders. Its lead candidate, DRLH01, is a potent anticoagulant targeting Coagulation factor X, currently in Phase 2 clinical trials. Another key program, DRLH03, is a multi-kinase inhibitor being evaluated for the treatment of various solid tumors. Derun Liuhe operates a comprehensive R&D center in Beijing and is recognized as a National High-tech Enterprise. The firm aims to address unmet medical needs by providing high-quality and affordable therapeutic options for patients globally.